Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. This innovation allows ADCs to selectively target cancer cells, sparing healthy tissue and reducing chemotherapy side effects. With advancements in linker technology and payload diversity, ADCs are breaking new ground in treating advanced or drug-resistant cancers. Allucent A-Team expert, Dr. Brian Barnett, shares insights into the evolution of ADCs, including key advancements and strategies to overcome challenges like dose optimization and off-target toxicity. As ADC technology progresses, it holds promise for treating previously untreatable cancers, reshaping the oncology landscape.
To delve deeper into how ADCs are paving the way for personalized and effective cancer therapies, read the full article, published in Labiotech.eu.
Dr. Brian Barnett, MD, Executive Medical Director, Oncology, Allucent
Prior to joining the industry, Dr. Brian Barnett, MD was a medical oncologist working in private practice. At Tulane University, he served as an Assistant Professor of Hematology and Medical Oncology, focusing on Regulatory T Cells in academic medicine. Along with Dr. Barnett’s experience in clinical practice, he has accumulated over 20 years of industry experience in translational research, medical monitoring, and regulatory meeting preparations. Dr. Barnett has held various impactful roles throughout his time in the pharmaceutical space, including Chief Medical Officer. At Allucent, Dr. Barnett provides the A-Team with expert guidance on both early- and late-stage drug and cell therapy clinical development.
Share This
